VISTIN PHARMA ASA (VISTN.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:VISTN - NO0010734122 - Common Stock
20.2 NOK
-0.3 (-1.46%)
Taking everything into account, VISTN scores 5 out of 10 in our fundamental rating. VISTN was compared to 54 industry peers in the Pharmaceuticals industry. VISTN has an excellent financial health rating, but there are some minor concerns on its profitability. VISTN has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year VISTN was profitable.
- In the past year VISTN had a positive cash flow from operations.
- In multiple years VISTN reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: VISTN reported negative operating cash flow in multiple years.
1.2 Ratios
- VISTN has a Return On Assets of 18.36%. This is amongst the best in the industry. VISTN outperforms 96.30% of its industry peers.
- VISTN's Return On Equity of 24.96% is fine compared to the rest of the industry. VISTN outperforms 72.22% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 20.45%, VISTN belongs to the top of the industry, outperforming 85.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.36% | ||
| ROE | 24.96% | ||
| ROIC | 20.45% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- VISTN has a Profit Margin of 17.16%. This is in the better half of the industry: VISTN outperforms 72.22% of its industry peers.
- In the last couple of years the Profit Margin of VISTN has declined.
- VISTN's Operating Margin of 20.82% is in line compared to the rest of the industry. VISTN outperforms 51.85% of its industry peers.
- VISTN's Operating Margin has improved in the last couple of years.
- VISTN has a Gross Margin of 66.40%. This is in the lower half of the industry: VISTN underperforms 61.11% of its industry peers.
- In the last couple of years the Gross Margin of VISTN has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.82% | ||
| PM (TTM) | 17.16% | ||
| GM | 66.4% |
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so VISTN is creating value.
- There is no outstanding debt for VISTN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- VISTN has an Altman-Z score of 7.53. This indicates that VISTN is financially healthy and has little risk of bankruptcy at the moment.
- VISTN has a Altman-Z score of 7.53. This is amongst the best in the industry. VISTN outperforms 88.89% of its industry peers.
- VISTN has a debt to FCF ratio of 0.32. This is a very positive value and a sign of high solvency as it would only need 0.32 years to pay back of all of its debts.
- VISTN's Debt to FCF ratio of 0.32 is amongst the best of the industry. VISTN outperforms 98.15% of its industry peers.
- VISTN has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
- With an excellent Debt to Equity ratio value of 0.07, VISTN belongs to the best of the industry, outperforming 85.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.32 | ||
| Altman-Z | 7.53 |
ROIC/WACC2.4
WACC8.52%
2.3 Liquidity
- VISTN has a Current Ratio of 2.23. This indicates that VISTN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.23, VISTN is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
- A Quick Ratio of 1.16 indicates that VISTN should not have too much problems paying its short term obligations.
- The Quick ratio of VISTN (1.16) is better than 64.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.23 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
- VISTN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.20%, which is quite impressive.
- Measured over the past years, VISTN shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.03% on average per year.
- Looking at the last year, VISTN shows a small growth in Revenue. The Revenue has grown by 7.38% in the last year.
- The Revenue has been growing by 13.56% on average over the past years. This is quite good.
EPS 1Y (TTM)27.2%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%11.83%
Revenue 1Y (TTM)7.38%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%2.84%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 11.48, the valuation of VISTN can be described as reasonable.
- 79.63% of the companies in the same industry are more expensive than VISTN, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 27.32. VISTN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.48 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 81.48% of the companies in the same industry are more expensive than VISTN, based on the Enterprise Value to EBITDA ratio.
- 83.33% of the companies in the same industry are more expensive than VISTN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.8 | ||
| EV/EBITDA | 7.68 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- VISTN has a Yearly Dividend Yield of 5.87%, which is a nice return.
- Compared to an average industry Dividend Yield of 1.59, VISTN pays a better dividend. On top of this VISTN pays more dividend than 96.30% of the companies listed in the same industry.
- VISTN's Dividend Yield is rather good when compared to the S&P500 average which is at 1.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.87% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- VISTN pays out 99.41% of its income as dividend. This is not a sustainable payout ratio.
DP99.41%
EPS Next 2YN/A
EPS Next 3YN/A
OSL:VISTN (1/21/2026, 7:00:00 PM)
20.2
-0.3 (-1.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-31 2025-10-31
Earnings (Next)02-16 2026-02-16
Inst Owners14.3%
Inst Owner ChangeN/A
Ins Owners4.89%
Ins Owner ChangeN/A
Market Cap895.67M
Revenue(TTM)454.83M
Net Income(TTM)78.06M
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.87% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP99.41%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.48 | ||
| Fwd PE | N/A | ||
| P/S | 1.97 | ||
| P/FCF | 13.8 | ||
| P/OCF | 11.24 | ||
| P/B | 2.86 | ||
| P/tB | 2.86 | ||
| EV/EBITDA | 7.68 |
EPS(TTM)1.76
EY8.71%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.46
FCFY7.25%
OCF(TTM)1.8
OCFY8.9%
SpS10.26
BVpS7.05
TBVpS7.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.36% | ||
| ROE | 24.96% | ||
| ROCE | 27.85% | ||
| ROIC | 20.45% | ||
| ROICexc | 20.64% | ||
| ROICexgc | 20.64% | ||
| OM | 20.82% | ||
| PM (TTM) | 17.16% | ||
| GM | 66.4% | ||
| FCFM | 14.27% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
F-Score7
Asset Turnover1.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.32 | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 68.54% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 68.54% | ||
| Profit Quality | 83.14% | ||
| Current Ratio | 2.23 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | 7.53 |
F-Score7
WACC8.52%
ROIC/WACC2.4
Cap/Depr(3y)280.38%
Cap/Depr(5y)338.81%
Cap/Sales(3y)11.99%
Cap/Sales(5y)13.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.2%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%11.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.38%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%2.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.53%
EBIT growth 3Y36.89%
EBIT growth 5Y38.44%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.99%
FCF growth 3YN/A
FCF growth 5Y158.58%
OCF growth 1Y3.04%
OCF growth 3Y99.03%
OCF growth 5Y41.62%
VISTIN PHARMA ASA / VISTN.OL FAQ
What is the fundamental rating for VISTN stock?
ChartMill assigns a fundamental rating of 5 / 10 to VISTN.OL.
What is the valuation status for VISTN stock?
ChartMill assigns a valuation rating of 4 / 10 to VISTIN PHARMA ASA (VISTN.OL). This can be considered as Fairly Valued.
Can you provide the profitability details for VISTIN PHARMA ASA?
VISTIN PHARMA ASA (VISTN.OL) has a profitability rating of 5 / 10.
What is the financial health of VISTIN PHARMA ASA (VISTN.OL) stock?
The financial health rating of VISTIN PHARMA ASA (VISTN.OL) is 8 / 10.
Can you provide the dividend sustainability for VISTN stock?
The dividend rating of VISTIN PHARMA ASA (VISTN.OL) is 5 / 10 and the dividend payout ratio is 99.41%.